Mergers & Acquisitions ·
Ocugen licenses OCU400 gene therapy to Roots for MENA region with up to $259M in potential payments
OCGNOcugen, Inc.
Ocugen entered into an exclusive license agreement with Roots Pharmaceutical Company WLL, granting rights to commercialize its modifier gene therapy OCU400 for retinitis pigmentosa in the Middle East and North Africa. Under the deal, Ocugen will receive up to $4 million in upfront and development milestones, plus up to $255 million in sales milestones, along with a 22% royalty on net sales. Ocugen retains global safety database ownership and will manufacture commercial supply under a separate agreement. Concurrently, Ocugen postponed its Special Meeting of Stockholders scheduled for December 22, 2026, specifically regarding the proposal to increase authorized common stock by 250 million shares, allowing additional time for shareholder consideration. Ocugen is a biotechnology company developing gene therapies for blindness diseases.